Early Onset Pulmonary Events and Management Strategies during the Treatment of
ALK Positive NSCLC Patients with Brigatinib.
10.3779/j.issn.1009-3419.2023.101.12
- Author:
Mingyi YANG
1
;
Weichi LUO
2
;
Qing ZHOU
1
Author Information
1. School of Medicine South China University of Technology, Guangzhou 510080, China.
2. Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Southern Medical University, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
- Publication Type:Journal Article
- Keywords:
Anaplastic lymphoma kinase;
Brigatinib;
Early-onset pulmonary events;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/genetics*;
Quality of Life;
Receptor Protein-Tyrosine Kinases;
Protein Kinase Inhibitors/adverse effects*
- From:
Chinese Journal of Lung Cancer
2023;26(4):281-290
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in signal dysregulation in kinase domain. As a new generation of potent ALK tyrosine kinase inhibitors (TKIs), Brigatinib was approved in China in March 2022 as a treatment for locally advanced or metastatic NSCLC patients with ALK rearrangement positive. Brigatinib significantly improved the survival, cranial efficacy and quality of life compared to Crizotinib in clinical trials. Brigatinib is generally well tolerated. Brigatinib has been one of the preferred treatments and an addition of options in ALK-rearranged NSCLC. Pulmonary toxicity is one of the adverse effects observed during the treatment of TKIs and deserves the intense attention of clinicians, despite of its low incidence rate. Pulmonary toxicity reported during the treatment of Brigatinib has shown distinct clinical presentations, such as early-onset (median time to onset, 2 days) and rapid tolerance and reversibility of symptoms. In view of this, the concept of early-onset pulmonary events (EOPEs) was proposed and established during the submission for regulatory review and approval. We focused on clinical characteristics, potential mechanism of etiology, and management strategies of EOPEs to provide clinicians evidence for better clinical decision support.
.
